文献速递前列腺癌

PROMISE:一个用于填补前列腺癌知识缺口真实世界临床-基因组数据库

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-08-06

PROMISE 是一个由 16 家学术机构组成的联盟,旨在建立去标识化临床与基因组数据及结局关联的数据库。2020 年初成立并创建 RedCap 数据库,截至 2021 年初已录入超过 1000 条记录,计划 2021 年底超过 2500 条。该平台可纳入临床试验中常被低估的人群,生成新假设并回答难以前瞻性研究的重要临床问题。

要点

  • PROMISE 联盟由 16 家学术机构于 2020 年初组成,建立去标识化临床-基因组数据库。
  • 截至 2021 年初已录入超过 1000 条患者记录,目标 2021 年底超过 2500 条。
  • 数据库涵盖常被临床试验低估的人群,可生成新假设并回答难以前瞻性研究的问题。

核心结论

  • PROMISE 联盟提供强大的临床-基因组平台,用于探讨和填补前列腺癌临床管理中基因组检测增加带来的数据缺口。

研究设计与样本

  • PROMISE 为多机构协作联盟,旨在建立去标识化临床与基因组患者数据仓库并与患者结局链接。

主要发现

  • PROMISE 联盟由 16 家学术机构于 2020 年初成立,并创建了安全的 RedCap 数据库。
  • 首条患者记录于 2020 年 4 月录入,截至 2021 年初已录入超过 1000 条记录。
  • 数据录入按计划进行,目标为 2021 年底超过 2500 条患者记录。

临床怎么用

  • 该平台可用于 interrogate 和解决前列腺癌临床管理中基因组检测增加带来的数据缺口。
  • 数据集纳入临床试验中常被低估的患者人群,生成新假设以指导进一步研究。
  • 可回答其他方法难以在前瞻性研究中调查的重要临床问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to enhance our characterization of advanced prostate cancer and further enable precision oncology. METHODS: The Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) is a consortium whose aims are to establish a repository of de-identified clinical and genomic patient data that are linked to patient outcomes. The consortium structure includes a (1) bio-informatics committee to standardize genomic data and provide quality control, (2) biostatistics committee to independently perform statistical analyses, (3) executive committee to review and select proposals of relevant questions for the consortium to address, (4) diversity/inclusion committee to address important clinical questions pertaining to racial disparities, and (5) patient advocacy committee to understand patient perspectives to improve patients' quality of care. RESULTS: The PROMISE consortium was formed by 16 academic institutions in early 2020 and a secure RedCap database was created. The first patient record was entered into the database in April 2020 and over 1000 records have been entered as of early 2021. Data entry is proceeding as planned with the goal to have over 2500 patient records by the end of 2021. CONCLUSIONS: The PROMISE consortium provides a powerful clinical-genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer. The dataset incorporates data from patient populations that are often underrepresented in clinical trials, generates new hypotheses to direct further research, and addresses important clinical questions that are otherwise difficult to investigate in prospective studies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Koshkin VS, Patel VG, Ali A, et al. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 34363009. doi:10.1038/s41391-021-00433-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。